First-in-Human Study of the CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia or High Risk-Myelodysplasia: Updated Safety, Efficacy, Pharmacokinetics and Pharmacodynamics
Ashish Bajel(The Royal Melbourne Hospital), Anthony S. Stein(University of Hohenheim), Stéphane de Botton(Université Paris-Saclay), C. Michel Zwaan(Hôpital Saint-Michel), Ioannis Mantzaris(Montefiore Medical Center), Sylvain Garciaz(Centre National de la Recherche Scientifique), Mojca Jongen‐Lavrencic(Erasmus MC Cancer Institute), Gu Mi(Eli Lilly (United States)), Kyle Jensen, Jennifer N. Saultz(Oregon Health & Science University), David Avigan(Beth Israel Deaconess Medical Center), David C. de Leeuw(Dutch Cancer Society), Dobrin Draganov, Timothy R. Wagenaar(AVEO Oncology (United States)), Abhishek Maiti(The University of Texas MD Anderson Cancer Center), Pinkal Desai(NewYork–Presbyterian Hospital), Nicolas Boissel(Inserm), Samira Ziti‐Ljajic(Sanofi (France)), Giovanni Abbadessa(Morristown Medical Center), Shaun Fleming(Peter MacCallum Cancer Centre), Gerwin Huls(University Medical Center Groningen), Martha Arellano(Memorial Sloan Kettering Cancer Center)
Cited by 24
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k